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Abstract
Focused ultrasound (FUS) is an incision-less intervention that is a FDA approved surgical treatment for various pathologies including uterine fibroids and bone metastases. Recent advances in magnetic resonance imaging thermometry and ability to use FUS across the intact calvarium has re-opened interest in the use of FUS in the treatment of neurological diseases. FUS currently has a European CE mark for use in movement disorders. However, it shows potential in the treatment of other neuropathologies including tumours and as a lesional tool in epilepsy. 
FUS may exert its therapeutic effect through thermal or mechanical fragmentation of intracranial lesions, or by enhancing delivery of pharmaceutical agents across the blood-brain barrier.
In this review we summarise the mechanisms, clinical applications and potential future of FUS for the treatment of neurological disease. We searched for and describe recently completed and on-going clinical trials investigating FUS for the treatment of neurological disorders. We identified phase one trials investigating utility of FUS in: movement disorders (including essential tremor and Parkinson’s disease), chronic pain, obsessive-compulsive disorder and cerebral tumours. Current literature also reports pre-clinical work exploring utility in epilepsy, neurodegenerative conditions (such as Alzheimer’s disease) and thrombolysis. 
Safety and early efficacy data is now emerging, suggesting that transcalvarial FUS is a feasible and safe intervention. Further evidence is required to determine whether FUS is an effective alternative in comparison to current neurosurgical interventions. The cost of requisite hardware is currently a barrier to widespread uptake in UK neurosurgical centres.
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Background
Several recent technology-driven developments are making neurosurgery less invasive. These include expanding use of endoscopy and improving stereotactic radiosurgical techniques. For example, stereotactic laser-induced thermal therapy, which has found relative success in surgery for the ablation of cerebral tumours1 and medically-refractive epilepsy2. However, these techniques still require an incision and the introduction of intracranial apparatus in order to reach and ablate the lesion. Whilst radiotherapy and radiosurgery is incision-less and image-guided, healthy brain parenchyma may be unduly exposed to radiation. 
FUS, also termed magnetic resonance imaging-guided focused ultrasound (MRgFUS) when combined with magnetic resonance imaging (MRI), is an advanced and therapeutic ultrasound (US) modality. FUS aims to deliver therapy through various mechanisms to intracranial targets such as thermal and mechanical ablation, blood-brain barrier (BBB) disruption and perhaps cortical excitation. 
FUS was first developed as a neurosurgical tool as early as 1942. The first record of FUS use for the brain is by Lynn et al who described the transcalvarial creation of cerebral lesions in animals and causing transient neurological deficit3. This was followed by the work of William and Francis Fry in 1955, who demonstrated the histological effects of US on neural tissue in animals4. Due to attenuation effects caused by the skull, early studies of FUS required craniectomy in order to deliver therapy to deep targets5,6. One of the pivotal developments in FUS research was enabling US delivery across the intact calvaria (largely credited to the work of Hynynen and colleagues from Brigham and Woman’s Hospital, Boston7). 
Avoiding an incision reignited interest in FUS as a potential therapeutic option. Although unproven, this may reduce the risk of postoperative infection and the length of in-patient stay. Pre- and intraoperative MRI guidance, fine precision and real-time monitoring of ablation theoretically allows intervention without compromising surrounding healthy brain.
To date, aA limiting factor of FUS in neurosurgical contexts has been combining it with a suitable tool to allow lesion localisation. Magnetic resonance (MR) thermometry now provides a means of monitoring the temperature of deep structures in order to predict damage delivered to the target and to allow alteration. Importantly, FUS may now be performed through the intact calvarium and without any skin incision. Although unproven, this may reduce the risk of postoperative infection and the length of in-patient stay. Pre- and intraoperative MRI guidance, fine precision and real-time monitoring of ablation theoretically allows intervention without compromising surrounding healthy brain. 
The USA Food and Drug Association (FDA) have approved FUS in the treatment of multiple non-neurosurgical pathologies (such as uterine fibroids, adenomyosis and bone metastases). The primary ‘clinic-ready’ FUS delivery device (the ExAblate® Neuro (inSightec; http://www.insightec.com/ (​http:​/​​/​www.insightec.com​/​​)) has not yet been granted FDA approval for use in neurological disease. Whilst this model has received the European CE Mark (December 2012) for the treatment of essential tremor, tremor-dominant Parkinson’s disease and neuropathic pain, it is not CE approved in cerebral tumours, lesional epilepsy and other conditions. 

Purpose of review
Here we provide an overview of the mechanism and applications of FUS. Our objective was to review the current literature and on-going clinical investigations, and to identify whether and how this technology may become an effective and available intervention for treatment of neurological disease in the UK.

Literature search
Studies and supporting literature for this review were identified using PubMed searches using the following keywords: ultrasound, acoustic, focus(s)ed, transcranial, transcalvarial, transskull. We also searched the ClinicalTrials.gov database (https://clinicaltrials.gov/ (​https:​/​​/​clinicaltrials.gov​/​​)) for on-going clinical trials using FUS in neurological disease. Further literature was identified through searching citation lists in reviewed studies. 

Principles of the procedure
In US transducers, acoustic energy is generated and detected using piezoelectric crystals that act as an interface between electrical and mechanical energy8. The acoustic waves, generated by these mechanical forces, are characterised by their frequency, amplitude and wavelength. As US waves traverse structures, they are attenuated. The attenuation is frequency dependent and is a result of scattering and absorption of the ultrasound beam. Most soft tissues, including brain tissue, have attenuation values that vary between 0.5 – 1 dB.cm-1.MHz-1. However the attenuation of US through the skull is much higher and of the order of 20 dB.cm-1.MHz-1.
Due to the short wavelength of the ultrasound wave (1.5mm at 1MHz), and the potential to focus the ultrasound beam, the acoustic energy can be localised with millimetre precision within soft tissues. Diagnostic sonography uses acoustic waves with frequencies in the range of 1-15 MHz. However, as US frequency increases so does the absorption of energy by tissues and attenuation of signal. This means that US from a transducer operating at high frequency can only penetrate to shallow targets. Moreover the high attenuation of the skull renders diagnostic transcalvarial US imaging of the brain difficult and has a limited number of clinical applications. Furthermore, high frequency US traversing the calvaria induces local hyperthermia in the soft tissues and bone as an adverse effect. Therefore, FUS transducers use frequencies in the range of 0.5–5 MHz 9, allowing acoustic energy to reach deeper intracranial targets. Use of frequencies in this range, when compared to higher frequencies more routinely used to image superficial soft tissues, reduces the very high attenuation effects of the skull and also the absorption of energy by intervening structures. 
FUS was proposed as a neurosurgical tool as early as 19425. In 1955, the first investigators demonstrated the histological effects of US on neural tissue in animals6. Due to attenuation effects caused by the skull, early studies of FUS required craniectomy in order to deliver therapy to deep targets7,8. One of the pivotal developments in FUS research was enabling US delivery across the intact calvaria (largely credited to the work of Hynynen and colleagues from Brigham and Woman’s Hospital, Boston9). Avoiding an incision reignited interest in FUS as a potential therapeutic option. 
Focusing low-frequency US from multiple transducers can ameliorate for loss of US energy10, facilitating delivery of a therapeutic level of energy to a target. A hemispherical device containing multiple transducers can strongly focus the US at intracranial targets whilst minimising attenuation11. (illustrated in Figure 1). Figure 21 illustrates shows the ExAblate® Neuro FUS helmet (InSightec; http://www.insightec.com/ExAblate-Neuro.html (​http:​/​​/​www.insightec.com​/​ExAblate-Neuro.html​)). This immobilises the patient in the surgical field and has more than 1000 US transducers that focus the US on the intracranial target. Figure 32 shows steps in the planning of FUS ablation for a cerebral tumour.
Another challenge in transcalvarial FUS is variance in beam propagation due to inhomogeneity of skull thickness and morphology. However, correction methods have been achieved using phase offsets to correct each transducer for propagation variances. Hynynen et al demonstrate the ability to achieve adequate US power through the skull by using two-dimensional phased arrays in order to eliminate phase distortion caused by the skull10. In addition, computed tomography imaging can offer information about skull density and morphology which can be programmed into the treatment algorithms in order to make phase and amplitude corrections to compensate for distortions across the bone12.
Commercially available FUS systems employ intraoperative thermal monitoring (MR thermometry) to allow near real-time evaluation of treatment effect. Thermal dose can be measured in real-time using MR spectroscopy and chemical-shift imaging13. The use of MR for thermometry has been well established and is currently used in other interventions such as MR-guided laser-induced thermal therapy1. Thermometry is important for two principle reasons. Firstly, estimated temperature at the intracranial target makes inference about treatment effectiveness. Secondly, thermometry allows for monitoring of unwanted ambient temperature.
The specific surgical protocol for FUS ablation has been described in further detail by Lipsman et al14.

Mechanisms of therapy
Thermal ablation
Thermal ablation has been previously explored as an intervention option in neurosurgery. For example, radiofrequency ablation15 and, more recently, laser-induced thermal therapy 1,2, have been employed to ablate cerebral lesions such as tumours and epilepsy foci. However, an animal study by Elias et al16 demonstrated a rapid decrease in thermal dose 2mm from the target in FUS, compared to radiotherapy that showed a sharp decrease at 2.5mm, and stereotactic radiosurgery which had a slow reduction of dose with 10% of the total dose present at 10mm from the target. Damage to surrounding brain and also the need for incision, has driven research to ascertain whether thermal ablation effect can be alternatively achieved with FUS.
Thermal ablation of intracranial lesions is becoming increasingly popular in neurosurgical practice1,2. FUS aims to deploy acoustic energy at a specific target as a lesioning tool. Signal attenuation at the target, as well as the traversed structures, is largely due to the conversion of acoustic energy to thermal energy and this constitutes one of the main mechanisms proposed for treating neurological disease. Coagulative necrosis of lesions is thought to occur in temperatures in excess of 55oC 17, however an animal study by Lyons et al show that acoustic energy applied for 50 minutes, heating brain parenchyma to 42 – 48oC was sufficient to cause necrosis18. Pre-clinical work in piglets has shown that FUS lesions remain limited to the target region after 48 hours, and that surrounding tissue oedema resolves within one week16. A key challenge in FUS is achieving a therapeutic dose of hyperthermia in the target while keeping surrounding brain parenchyma below 42.5oC 19.
Cavitation
FUS may be manipulated further in order to intervene through other mechanisms. At the focus of the US beams, acoustic energy may also be converted into mechanical forces by inducing pressure fluctuation in tissue. Cavitation can be achieved by the interaction of high-frequency US with gas-filled microbubbles20. These gas-filled microbubbles are likely to be created by interstitial liquid changing into a vapour due to the temperature rise caused by the focal deposition of acoustic energy. These bubbles, once formed, can oscillate stably about their equilibrium radius – this is referred to as non-inertial (stable) cavitation or the focussed ultrasound beam can cause these microbubbles to expand to many times their equilibrium radii causing the microbubbles to collapse violently potentiating mechanical disturbance at the site of this collapse. This is referred to as inertial (or transient) cavitation. This process can cause necrosis or may only temporarily disrupt the permeability of cell membranes21.
Disruption of the blood-brain barrier
Drug delivery across the blood brain barrier (BBB) remains challenging. Transient disruption of the BBB may allow large-molecular therapeutic agents to reach intracranial lesions and exert effect (and perhaps reduce toxicity by allowing more conservative dosing regimes). However, to maintain the vital roles of the BBB, the method would need to be local, transient and reversible. Whilst some other options of evading the BBB have been described, such as topical treatment with chemotherapy wafers22, FUS may offer a non-invasive option for the augmentation of therapies.
FUS has been explored extensively at an animal model level as a method to disrupt the BBB. Early studies have shown the BBB dysfunction that accompanies lesion ablation using FUS9, but it was not until a study by Hynynen et al that it was shown to be achievable without the damaging effects of local hyperthermia23. As with mechanical ablation, this effect is achieved through the use of microbubbles by reducing the FUS intensity required to cause effect on the BBB and avoiding the adverse effects of hyperthermia. This technique is thought to leave the BBB disrupted for 6-24 hours14. FUS has been employed in experimental studies of BBB disruption in the context of delivery of the drugs Herceptin24, doxorubicin25 and temozolomide26. FUS may also have a place in the symptomatic treatment of drug-resistant epilepsy, transiently opening the BBB to allow the action of drugs in seizure clusters in order to deliver therapeutic, yet systemically acceptable, doses27.
An in-depth description of the mechanisms of BBB dysfunction using FUS is beyond the scope of this review, but been extensively summarised by other authors9,28.

Cortical excitation
FUS may have a role in cortical excitationneuromodulation. A study by Kim et al investigated the use of FUS to stimulate the thalami of Sprague–Dawley rats29. The investigators used 2-deoxy-2-[18F]fluoro-d-glucose positron emission tomography in order to detect the region of neuromodulation excitation and measured the time taken for motor response to occur. The study found that, relative to alternative stimulation methods, FUS neuromodulation induced cortical excitation occurs with some delay, potentially indicating that the mechanism is by nonelectrical modulation. FUS has only recently been demonstrated in humans in studies using transcranial stimulation of the cortex30. The effects of FUS at the primary somatosensory cortex demonstrated attenuation of somatosensory evoked potentials that were elicited by median nerve stimulation.

Clinical applications
As discussed, the advances surrounding the ability to perform FUS across the intact calvaria have allowed further steps towards translation into neurosurgery. The only indication currently approved under the European CE mark is the treatment of movement disorders. In this section we discuss both the recently completed and on-going clinical trials. Trials are identified using the National Clinical Trials identifier number coding (www.ClinicalTrials.gov (​http:​/​​/​www.ClinicalTrials.gov​)). 
Movement disorders
To date, two clinical trials using FUS thalamotomy for treatment of essential tremor have been completed and published. The first is an open labelled, uncontrolled pilot trial by Elias et al from the University of Virginia31. The investigators used FUS thalamotomy (unilateral ventral intermediate nucleus of the thalamus) in patients with medically refractive essential tremor. The FUS intervention achieved a mean maximal temperature of 58.5 ± 2.5°C (range, 54 to 63) at the lesion using a mean of 17.9 ± 4.6 sonications (range, 11 to 26). Despite the sample size in the pilot study being small (n = 15), the effects were promising. Tremor, measured using the Clinical Rating Scale for Tremor (ranging from 0 to 160), was reduced from 54.9 at baseline to 24.3 at 12 months post-procedure. Similarly, the hand tremor subscore (ranging from 0 to 32) reduced from 20.4 at baseline to 5.2 at 12 months post-procedure. Disability and quality of life measures also showed improvement after the therapy. 
The second study was conducted by Lipsman et al at the University of Toronto32 and similarly investigated the use of FUS thalamotomy to treat four patients with medically refractive essential tremor. Neuroimaging and clinical evaluation was performed at baseline, one-month post procedure and three months post procedure. The FUS therapy achieved focal hyperthermia at a mean temperature of 59.3oC (range 56 oC – 63 oC) using a mean of 22.5 sonifications (range 12 – 29). Mean reduction on the Clinical Rating Scale for Tremor of the treated hand was 89.4% at one month and 81.3% at three months. These small studies have led to the design and commencement of a InSightec sponsored, eight-centre, double blinded, randomised, clinical trial examining the effectiveness and safety of FUS thalamotomy for essential tremor versus sham FUS thalamotomy (NCT01827904). The investigators plan to follow 72 patients for one year post-procedure and reach trial completion by September 2015. This will be an important outcome since there is currently no long termlong-term efficacy data in FUS for this purpose. 
A major limitation of theseis studiesy , and others like it, is that the FUS procedure is not compared to current practices such as deep brain stimulation (DBS). One study of DBS showed 40% mean reduction of tremor score (Clinical Rating Scale for Tremor) in 25 patients with essential tremor at three months after surgery33. Another study of DBS in essential tremor showed an 80.4% reduction of tremor (on the Fahn-Tolosa-Marin tremor scale) at an average of 56.9 months follow up34. This is compared to 75% reduction at one year claimed by Elias et al31 and 81.3% reduction at three months claimed by Lipsman32. However, head-to-head trials with comprehensive outcome data are required to truly compare these interventions.
There have been six phase one clinical trials using FUS in the treatment of Parkinson’s disease. There are a number of on-going safety trials that aim to identify the adverse effects arising from FUS ablation of the ventral medial thalamus (Vim) with thalamotomy for tremor-dominant disease (NCT02252380, NCT01772693, NCT02246374). This includes a trial that is accepting patients with a number of other movement disorders, including essential tremor, Holmes tremor, Wilson's disease, Huntington's disease, dystonia, tardive dyskinesia and orofacial dyskinesias (NCT02252380). Only one of these studies, conducted at the University of Virginia (Virginia, USA) and the Swedish Medical Center (Washington, USA) is a randomised controlled trial (NCT01772693). This trial will investigate the efficacy and adverse effects of FUS compared to a sham procedure in 30 patients at three months post-procedure. Due to the sham control, again it is not possible to comment on the efficacy of FUS compared to current best practice. Three other small trials have registered and will attempt to treat dyskinesia with unilateral lesion of globus pallidus (NCT02003248, NCT02263885, NCT02347254).
Currently completed and registered clinical trials have been summarised in Table 1.

Obsessive-compulsive disorder
Chang et al at Yonsei University are investigating FUS for the treatment of obsessive-compulsive disorder (NCT01986296). This is a phase one, feasibility study investigating the use of FUS in order to ablate any of the ainterior cingulate cortex, anterior limb of internal capsule, ventral striatum or subgenual cingulate cortex in 15 patients with the disorder. The study aims to assess the effectiveness of FUS in the reduction of severity of obsessive-compulsive disorder at six months after the treatment (using the Yale-Brown Obsessive-Compulsive Disorder Scale, Hamilton Depression Rating Scale, and Hamilton Anxiety Rating Scale).
Neuropathic pain
Investigators from two hospitals in Zurich have published data on the use of FUS central lateral thalamotomies in the treatment of neuropathic pain. The first study in 2009 examined the effects in nine patients with medically-refractive neuropathic pain35 and found that thermal ablations of 3-5mm in diameter using temperatures of 51oC to 60oC resulted in a mean of 68% reduction (range 30-100%) of pain on the visual analog scale at 48 hours post-operatively. This study was followed up in 2012 in a study which achieved 3-4mm thermal ablation at temperatures between 51°C and 64°C in 12 patients36. This study achieved mean pain relief of 49% in patients who attended the three-month follow-up (9/12 patients) and 57% at the one-year follow-up (8/12 patients). A study of DBS in neuropathic pain by Boccard showed that 39 of 59 (66%) patients benefited from the procedure37. From those patients, 38 patients were followed and demonstrated 38.7% improvement in pain since baseline. Again, head-to-head trials are required to make a meaningful comparison.
Depression
Only one trial is registered, to date, that will attempt to treat medically-refractory major depressive disorder. The trial is a single-centre (Yonsei University), single arm study that will aim to treat five patients. The primary outcome is the comparison of the Hamilton Depression Rating Scale-17 between baseline and six months. The trial is due to finish in October 2017.
Cerebral tumours
The first phase one clinical trial of FUS for the treatment of cerebral tumours was conducted by a group from the University of Arizona. They explored use of FUS before radiotherapy in 15 patients with either anaplastic astrocytoma or glioblastoma multiforme5. 10/15 of the patients had previously undergone debulking surgery and/or radiotherapy. Since the study pre-dated the invention of the hemispherical device, this intervention required a craniectomy that was 1.5cm wider than the tumour in all directions. Monitoring of thermodynamics was performed with thermoprobes at the intratumoural and peritumoural regions. The mean minimum and maximum intratumoural temperatures achieved across cases were 39.5oC and 43.0oC respectively. Post mortem results confirmed pathological changes associated with the hyperthermia caused by FUS. Another phase one study investigated three patients who underwent craniectomy seven to ten days before FUS thermal ablation of recurrent glioblastoma multiforme6. This study achieved temperatures of 60 to 90oC at the target volume for 12 to 20 seconds at a time and demonstrated the FUS treatment effect on both postoperative MRI and pathology.
After pre-clinical testing in three Rhesus monkeys38, McDannold et al, from Brigham and Women’s Hospital, Boston USA, published the results of a test of feasibility for the use of transcalvarial FUS for the fragmentation of glioblastoma multiforme in three patients17. The investigators found success in focusing the US across the calvaria in order to reach the target, but the power achieved did not allow successful thermal coagulation. This study has allowed the pursuit of non-invasive, transcalvarial FUS in tumour surgery and consequently there are a number of on-going clinical trials investigating the use of FUS in the thermal ablation of cerebral tumours (summarised in Table 2). Each of these FUS studies aims to assess the safety of FUS in ten patients (NCT00147056, NCT01698437 and NCT01473485). 
To our knowledge there is only one on-going clinical trial in the use of FUS to include BBB dysfunction in order to deliver therapy to cerebral tumours. A single-group assignment, open-label trial examining BBB dysfunction for doxorubicin is currently being conducted at the Sunnybrook Center in Toronto (NCT02343991). This is firstly a feasibility and safety study in order to investigate the frequency and severity of adverse effects of the procedure in ten patients. The trial is due to be completed in December 2015.

Future applications
FUS may be an alternative to minimally invasive, stereotactic, catheter guided thermal ablation for selective amygdalahippocampectomy or other pathologies such as hypothalamic hamartoma. FUS has been investigated in animal models of Alzheimer’s disease in attempts to increase antibody delivery to the brain and thus decrease plaque burden39. A cadaveric study by Monteith et al has demonstrated the potential of using FUS sonothrombolysis in liquefying clots consequent to intracerebral haemorrhage40. Similarly, FUS has been proposed as a treatment modality for embolic stroke, either through direct mechanical action, or by potentiating the action of thrombolytic agents41. Even third ventriculostomy has been achieved in a pig model, by using FUS in combination with craniectomy42.

Future challenges
The first challenge is ensuring that FUS is a safe intervention in the treatment of neurological disease. Whilst FUS can be considered a ‘non-invasive’ intervention, it may induce significant collateral damage to surrounding tissues. For example, in one study FUS caused a hemiparesis after accidental focus in the midbrain6. The vasculature is an important consideration in planning the surgical region-of-interest since there has already been one case of cerebral haemorrhage which may have been related to FUS intervention17. Another concern in FUS is that harmful hyperthermia may still be induced at the skull and soft-tissues. Many other theoretical adverse effects, for example febrile seizures43, have yet to be reported. 
After safety is ensured, larger clinical trials are required in order to assess the efficacy of the intervention. Whilst one study has investigated MRI and histological features of FUS compared to radiofrequency and Gamma Knife radiosurgery16, large-scale and high quality trials are called for in order to determine the efficacy of FUS compared to current best practice. Furthermore, whilst we can speculate on the advantages and disadvantages over FUS compared to other emerging minimally invasive options (compared in Table 3) there has been no experimental comparison.  The cost of requisite hardware may currently be a barrier to widespread uptake in UK., Initial investment cost of FUS is estimated to total to over 30 million pounds44. however However in the long term FUS may be considered relatively cost-effective since the procedure may be offered as a day case surgery with no general anaesthetic and no further equipment or implants.
Recent advances such as real time MR monitoring and the ability to offer an incision-less and transcalvarial approach, investigation of FUS as a treatment option in neurological disease is being re-explored and is gaining momentum globally. In order to be considered as a tool within a range of therapeutic options in UK neurosurgery, FUS requires further validation in regards to safety, long-term efficacy, efficacy compared to current best practice and cost-effectiveness.

Legend
Figure 1. Illustration of the mechanism of focused ultrasound. Multiple transducers arranged in a hemispherical array allow ablation of an intracranial target without incision. However, the design is currently limits application of the technique to deep lesions.

Figure 21. Picture of the ExAblate® Neuro (inSightec; http://www.insightec.com/ (​http:​/​​/​www.insightec.com​/​​)). Image provided by InSightec and published with permission.
Figure 32. Picture of the focused ultrasound ablation of a glioblastoma in one patient. (A) Coronal T2-weighted MRI of a patient in the FUS device. (B) The region of the skull derived from CT images is co-registered with the MRI data. The target paths from each transducer are plotted on coronal (C) and sagittal (F) T2-weighted MR images to allow surgical planning. (D & E) Pre-operative contrast enhanced T1-weighted MRI in order to estimate the tumour margin. Images kindly provided by Dr. Nathan McDannold (Associate Professor, Department of Radiology, Harvard Medical School, USA). These images are sourced from the McDannold et al investigating Transcranial ultrasound in three patients with glioblastoma15.
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Identifier	Condition(s)	Phase	Status	No. of centres	Intervention	Control group	Primary outcomes	Secondary outcomes	Predicted enrolment
NCT01827904	Essential tremor	1	On-going	8	FUS thermal thalamotomy	Sham thermal ablation	1. Severity of adverse effects up to 12 months	1. Effectiveness of therapy to improve tremor (using Clinical Rating Scale for Tremor) at 12 months	72
NCT 02037217	Essential tremor	1	On-going	1	FUS thermal thalamotomy	None	1. Incidence and severity of adverse events in the first three months	1. Effectiveness of therapy to improve tremor (using Clinical Rating Scale for Tremor) at three months	10
NCT02289560	Essential tremor	1	On-going	6	FUS thermal thalamotomy	None	1. Incidence and severity of adverse effects	1. Effectiveness of therapy to improve tremor (using Clinical Rating Scale for Tremor) at 12 months	50
NCT01772693	Parkinson’s disorder	?	On-going	2	FUS thermal ablation of the Vim thalamic nucleus	Sham Vim thalamotomy	1. Severity of adverse events at time of procedure	1. Outcome on Unified Parkinson's Disease Rating Scale at three months. 2. Incidence of adverse events at time of procedure3. Incidence and severity of adverse events at two years	30
NCT02252380	Essential tremor, Holmes tremor, Parkinson's disease, Wilson's disease, Huntington's disease, dystonia, tardive dyskinesia, orofacial dyskinesias	1	On-going	1	FUS thermal ablation of the Vim thalamus or the globus pallidus	None	1. Severity of adverse effects at time of procedure		10
NCT02003248	Parkinson’s disorder	1	On-going	1	FUS thermal ablation for pallidotomy for levodopa Induced dyskinesia	None	1. Outcome on the Unified Dyskinesia Rating Scale and part four of the Unified Parkinson's Disease Rating Scale up to 12 months		5
NCT02246374	Parkinson’s disorder	1	On-going	1	FUS thermal ablation of the subthalamic nucleus	None	1. Severity of adverse events at time of procedure		10
NCT02263885	Parkinson’s disorder	1	On-going	Not reported		None	1. Severity of adverse events at time of procedure and at six months		20
NCT02347254	Parkinson’s disorder	1	On-going	1	FUS pallidotomy for levodopa induced dyskinesia	None	1. Number of adverse events at the time of procedure	1. Severity of adverse events at the time of procedure	6

Table 1. On-going clinical trials investigating the efficacy and applicability of focused ultrasound for movement disorders. NCT, National Clinical Trials identifier number (www.ClinicalTrials.gov).

Identifier	Phase	Status	No. of centres	Intervention	Control group	Primary outcomes	Secondary outcomes	Predicted enrolment
NCT00147056	1	On-going	2	FUS thermal ablation.	None	1. Number of serious adverse events up to three months2. Number of minor adverse events up to three months	1. Evaluation of ablation using contrast MRI	10
NCT01698437	1	On-going	1	FUS thermal ablation.	None	1. Lesion size at three months2. Number of adverse events up to three months		10
NCT01473485	1	On-going	1	FUS thermal ablation.	None	1. Number of adverse events at the time of surgery		10
NCT02343991	1	On-going	1	Blood-brain barrier disruption using FUS with doxorubicin 	None	1. Number of adverse events at the time of surgery	1. Severity of adverse events at the time of surgery	10

Table 2. On-going clinical trials investigating the efficacy and applicability of focused ultrasound for cerebral tumours. NCT, National Clinical Trials identifier number (www.ClinicalTrials.gov (​http:​/​​/​www.ClinicalTrials.gov​)). 





	Advantages	Disadvantages
Focused ultrasound	Incision-lessno risk of infectionreduces in-patient stayReal-time observation of effect with MRI allowing intraoperative changesProven ability to interact with microbubbles to disrupt blood-brain barrierallows chemotherapy to cross the blood-brain barrier	Limited to deep targetsSmall evidence for efficacyExpensive (>30 million pounds as estimated (44))Only currently licensed for essential tremorSkull heating
Stereotactic radiosurgery	StereotacticImage-guidedIncision-less	Wider zone of collateral damage (10mm) compared to FUS (2mm) (16)Generally reserved to well-circumscribed lesionsLatent risks of ionising radiation
Laser-induced thermal therapy	Real-time feedback with MRI allowing intraoperative changes	Requires an incision & burr holeBlind passage of laser to the lesionRisk of dissection to parenchyma and vesselsMultiple lasers may be required for complex lesions

Table 3. Comparison focused ultrasound to competing treatment options – stereotactic radiosurgery and laser-induced thermal therapy.
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